Ossianix Announces Strategic Research Collaboration with Lundbeck
PHILADELPHIA -- January 6, 2014
Ossianix, Inc. today announced a strategic research collaboration with
Lundbeck A/S. This collaboration follows a previous investment in 2012. The
collaboration uses Ossianix’s innovative single domain antibody platform based
on the shark VNAR structure and will focus on two projects.
The first project will further develop Ossianix’s VNAR antagonists targeting
an ion channel for the treatment of pain. The second project utilizes
Ossianix’s Blood Brain Barrier targeting technology for the development of
bispecific biopharmaceuticals to treat CNS disorders. The Ossianix platform
has the advantage of targeting antibodies to the CNS where existing antibodies
have proven less than ideal due to poor bioavailability. Lundbeck will fund
the research plan with development and regulatory milestones.
Dr. Frank Walsh, Ossianix CEO, stated: “We are pleased to continue and extend
our strategic relationship with Lundbeck. The VNAR platform has shown its
potential in isolating potent and specific biopharmaceuticals to difficult
drug targets and in developing strategies for CNS drug delivery. We will now
proceed in partnership with Lundbeck with the goal of moving products to the
Dr. Kim Andersen, Vice President of Research for Lundbeck, said: “We at
Lundbeck have been impressed by the progress Ossianix has made following our
initial investment and we look forward to a further productive relationship.
This will allow us to develop novel biopharmaceuticals for very difficult CNS
Ossianix is a privately held research company based in Philadelphia, PA with
research laboratories in the UK. It develops novel biopharmaceuticals for a
number of therapeutic areas including CNS. The company utilizes the versatile
single domain shark VNAR scaffold to engineer unique differentiated products
in a variety of formats including monospecific and bispecifics. The company
was founded by two former senior executives from Wyeth and Pfizer, Drs. Frank
S. Walsh and Corey S. Goodman. Ossianix is currently funded by Lundbeck,
BioAdvance and other angel investors as well as non-dilutive grants. For more
information please visit www.ossianix.com.
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
highly committed to improving the quality of life of people living with brain
diseases. For this purpose, Lundbeck is engaged in the entire value chain
throughout research, development, production, marketing and sales of
pharmaceuticals across the world. The company’s products are targeted at
disorders such as depression and anxiety, psychotic disorders, epilepsy,
Huntington’s, Alzheimer’s and Parkinson’s diseases. Lundbeck’s pipeline
consists of several mid- to late- stage development programs.
Lundbeck employs more than 5,800 people worldwide, 2,000 of whom are based in
Denmark. With employees in 57 countries and products which are registered in
more than 100 countries, Lundbeck has research centers in Denmark, China and
the United States and production facilities in Italy, France, Mexico, China
and Denmark. Lundbeck generated revenue of approximately DKK 15 billion in
2012. For additional information, please visit www.lundbeck.com.
BioAdvance is a leading early-stage life sciences investor, with over $24M
committed to 57 life science start-up companies and academic technologies. To
date ten portfolio companies have been acquired and almost $1.6B in follow-on
capital (including M&A) has been attracted. The BioAdvance portfolio companies
are developing 60 products to treat diseases such as cancer, diabetes,
Alzheimer’s and infectious disease, and seven products have been approved by
the FDA to date.
For more information or to apply for funding please visit www.bioadvance.com.
Frank S Walsh CEO
Press spacebar to pause and continue. Press esc to stop.